X4 Pharmaceuticals (XFOR) Net Equity Issued and Repurchased (2017 - 2025)
X4 Pharmaceuticals' (XFOR) quarterly Net Equity Issued and Repurchased came in at $146.0 million in Q4 2025, up 68.05% quarter-over-quarter from $86.9 million in Q3 2025.
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Net Equity Issued and Repurchased (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals (XFOR) has reported Net Equity Issued and Repurchased for 3 consecutive years, with $146.0 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $146.0 million; the trailing twelve-month figure through Dec 2025 stood at $232.9 million (up 353.32% YoY), and the FY2025 full-year result was $238.5 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased improved to $146.0 million in Q4 2025 per XFOR's latest filing, from $86.9 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $146.0 million in Q4 2025 and bottomed at $2000.0 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | - |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | - |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | 141.90 Mn |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | - |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 146.04 Mn |
| Sep 30, 2025 | 86.91 Mn |
| Dec 31, 2023 | 51.38 Mn |
| Sep 30, 2023 | 2,000.00 |
| Sep 30, 2017 | 5.00 Mn |
| Jun 30, 2017 | 253,000.00 |